Activation of peripheral blood CD14+ monocytes occurs in diabetes

Diabetes

Volumn 54, Issue 9, 2005, Pages 2779-2786

  Cipolletta, Christine ^a   Ryan, Kathryn E ^b   Hanna, Elinor V ^b   Trimble, Elisabeth R ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD36 ANTIGEN; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SCAVENGER RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL ISOLATION; CELL SURFACE; CONTROLLED STUDY; DIABETES CONTROL; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD36; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELL ADHESION; CHEMOKINE CCL2; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MONOCYTES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, LDL; RNA, MESSENGER; VASCULAR CELL ADHESION MOLECULE-1;

EID: 24144481801     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.9.2779     Document Type: Article

References (47)

1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105:1135-1143, 2002
2. Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation 109 (Suppl. 1):II27-II33, 2004
3. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB: C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 24:969-974, 2004
4. Kampus P, Kals J, Ristimae T, Fischer K, Zilmer M, Teesalu R: High-sensitivity C-reactive protein affects central haemodynamics and augmentation index in apparently healthy persons. J Hypertens 22:1133-1139, 2004
5. Koenig W, Sund M, Frohlick M, Fischer H-G, Lowel H, Doling A, Hutchinson WL, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242, 1999
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565, 2002
7. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397, 2004
8. Verma S, Li S-H, Badiwala MV, Weisel RD, Fedak PWM, Li R-K, Dhillon B, Mickle DG: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105:1890-1896, 2002
9. Hattori Y, Matsumura M, Kasai K: Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 58:186-195, 2003
10. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999
11. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology and management. J Am Med Assoc 287:2570-2581, 2002
12. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation 108:414-419, 2003
13. Meigs JB, Hu FB, Rifai N, Manson JE: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. J Am Med Assoc 291:1978-1986, 2004
14. Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH: Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. J Intern Med 250:415-421, 2001
15. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin-6 and risk of developing type 2 diabetes mellitus. J Am Med Assoc 286:327-334, 2001
16. Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, Fazia M, Tumini S, De Cesare D, Pomilio M, Pierdomenico SD, Di Gioacchino M, Cuccurullo F, Mezzetti A: Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 25:1829-1834, 2002
17. Piemonti L, Calori G, Mercalli A, Latttuada G, Mono P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G: Fasting plasma leptin, tumor necrosis factor-α receptor 2 and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women. Diabetes Care 26:2883-2889, 2003
18. Kavanagh IC, Symes CE, Renaudin P, Nova E, Mesa MD, Boukouvalas G, Leake DS, Yaqoob P: Degree of oxidation of low density lipoprotein affects expression of CD36 and PPARγ, but not cytokine production, by human monocyte-macrophages. Atherosclerosis 168:271-282, 2003
19. Iwashima Y, Eto M, Hata A, Kaku K, Horiuchi S, Ushikubi F, Sano H: Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 277:368-380, 2000
20. Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M: Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thomb Vasc Biol 21:1464-1469, 2001
21. Tabata T, Mine S, Kawahara C, Okada Y, Tanaka Y: Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem Biophys Res Commun 305:380-385, 2003
22. Nicholson AC: Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc Med 14:8-12, 2004
23. McEneny J, O'Kane MJ, Moles KW, McMaster C, McMaster D, Mercer C, Trimble ER, Young IS: Very low density lipoprotein subfractions in type II diabetes mellitus: alternations in composition and susceptibility to oxidation. Diabetelogia 43:485-493, 2000
24. Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, Kumon Y, Hashimoto K: Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 53:297-302, 2004
25. Stephan ZF, Yurachek EC: Rapid fluorometric assay of LDL receptor activity by Dil-labeled LDL. J Lipid Res 34:325-330, 1993
26. Teuper D, Thiery J, Walli AK, Seidel D: Determination of LDL- and scavenger-receptor activity in adherent and non-adherent cultured cells with a new single-step fluorometric assay. Biochim Biophys Acta 1303: 193-198, 1996
27. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408, 2001
28. Worthylake RA, Lemoine S, Watson JM, Burridge K: RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154:147-160, 2001
29. Rodenburg RJ, van den Hoogen FH, van de Putte LB, van Venrooy WJ: Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF alpha, IL-1beta, and IL-8 mRNA levels: a comparison of monocyte isolation procedures. J Immunol Methods 221:169-175, 1998
30. Tsukamoto K, Knoshita M, Kojima K, Mikuni Y, Kudo M, Mori M, Fujita M, Hone E, Shimazu N, Teramoto T: Synergically increased expression of CD36, CLA-1 and CD68, but not of SR-A and LOX-1, with the progression to foam cells from macrophages. J Atheroscler Thromb 9:57-64, 2002
31. Nicholson AC, Frieda S, Pearce A, Silverstein RL: Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines: evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 15:269-275, 1995
32. Boullier A, Gillotte KL, Horkko S, Green SR, Friedman P, Dennis EA, Witztum JL, Steinberg D, Quehenberger O: The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 275:9163-9169, 2000
33. Pfeiffer JR, Howes PS, Waters MA, Hynes ML, Schnurr PP, Demidenko E, Bech FR, Morganelli PM: Levels of expression of Fcγ receptor IIA (CD32) are decreased on peripheral blood monocytes in patients with severe atherosclerosis. Atherosclerosis 155:211-218, 2001
34. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
35. Fu Y, Luo N, Lopes-Virella MF, Garvey WT: The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 165:259-269, 2002
36. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P: Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970-2973, 2000
37. Jostarndt K, Rubic T, Kuhn H, Anthosen MW, Andera L, Gellert N, Trottman M, Weber C, Johansen B, Hrboticky N, Neuzil J: Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferators-activated receptor-γ-dependent way. Biochem Pharmacol 67:841-854, 2004
38. 12,14-PGJ2 and the ligation of PPARγ. J Clin Invest 112:945-955, 2003
39. Hudson BI, Bucciarelli LF, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM: Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419:80-88, 2003
40. Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA: Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes. Atherosclerosis 167:129-134, 2003
41. Dorffel Y, Latsch C, Stuhmuller B, Schrieber S, Scholze S, Burmester DR, Scholze J: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34:113-117, 1999
42. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P: Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110:1564-1571, 2004
43. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P: Suppression of nuclear factor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86:1306-1312, 2001
44. Chinetti G, Fruchart J-C, Staels B: Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol 14:459-468, 2003
45. Cock TA, Houten SM, Auwerx J: Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 5:142-147, 2004
46. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998
47. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82, 1998